Want to see IL:BLRX full AI Analyst Report?
BLRX Stock Chart & Stats
1.50
0.10(6.67%)
At close: 4:00 PM EDT
1.50
0.10(6.67%)
Day’s Range― - ―
52-Week Range1.10 - 2.30
Previous CloseN/A
Volume0.00
Average Volume (3M)3.77M
Market Cap
₪35.84M
Enterprise Value33.16M
Total Cash (Recent Filing)₪12.99M
Total Debt (Recent Filing)₪7.94M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 18, 2026EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,986,929,700
10 Day Avg. Volume2,720,650
30 Day Avg. Volume3,770,497
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)₪1.95M
Bulls Say, Bears Say
Bulls Say
Differentiated Oncology PipelineGLIX1 targets serious cancers with limited treatment progress and combines several potentially differentiated attributes, including oral dosing, blood-brain barrier penetration, and activity against glioma stem cells. These characteristics could support meaningful clinical and partnering value if ongoing studies confirm the preclinical profile.
Advancing Clinical ProgramsProgress across two clinical programs provides multiple development paths rather than dependence on a single trial. GLIX1 is advancing through planned cohorts and the pancreatic cancer study is enrolling well, creating identifiable catalysts from future safety, efficacy, and interim analyses over the coming quarters.
Royalty Revenue And Funding RunwayAPHEXDA royalties provide a commercial revenue stream alongside milestone-driven agreements, while reported cash and the planned offering are expected to fund operations into the first half of 2027. This runway gives management time to advance trials and pursue value-creating milestones without an immediate funding gap.
Bears Say
Severe Revenue Deterioration And LossesThe sharp revenue contraction shows that current commercial traction is weak and highly volatile, while the deeply negative margin indicates that development costs substantially exceed income. Until royalties or partnerships scale, the company has limited internally generated support for its ongoing oncology investment.
Persistent Cash Burn And Funding DependenceNegative operating and free cash flow mean the business is not currently self-funding its development strategy. Even though burn has improved from 2024, continued cash usage leaves future trial execution dependent on royalties, milestones, offerings, or other financing, which can constrain strategic flexibility.
Clinical And Commercialization UncertaintyThe main pipeline asset has not yet produced clinical data and remains focused on establishing dose and preliminary efficacy, leaving substantial development risk. Separately, APHEXDA growth depends on external sales execution and changing treatment practices, limiting visibility into near-term commercial expansion.
Bioline Rx News
BLRX FAQ
What was BioLineRX Ltd.’s price range in the past 12 months?
BioLineRX Ltd. lowest stock price was 1.10 and its highest was 2.30 in the past 12 months.
What is BioLineRX Ltd.’s market cap?
BioLineRX Ltd.’s market cap is ₪35.84M.
When is BioLineRX Ltd.’s upcoming earnings report date?
BioLineRX Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 39 days.
How were BioLineRX Ltd.’s earnings last quarter?
BioLineRX Ltd. released its earnings results on Aug 31, 2026. The company reported 0 earnings per share for the quarter.
Is BioLineRX Ltd. overvalued?
According to Wall Street analysts BioLineRX Ltd.’s price is currently Overvalued.
Does BioLineRX Ltd. pay dividends?
BioLineRX Ltd. does not currently pay dividends.
What is BioLineRX Ltd.’s EPS estimate?
BioLineRX Ltd.’s EPS estimate is -0.31.
How many shares outstanding does BioLineRX Ltd. have?
BioLineRX Ltd. has 2,986,929,700 shares outstanding.
What happened to BioLineRX Ltd.’s price movement after its last earnings report?
BioLineRX Ltd. reported an EPS of 0 in its last earnings report. Following the earnings report the stock price went down -6.667%.
Which hedge fund is a major shareholder of BioLineRX Ltd.?
Currently, no hedge funds are holding shares in IL:BLRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioLineRX Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.